Outpatient Induction of Labor With Oral Misoprostol: A Multicenter Randomized-controlled Trial

  • STATUS
    Recruiting
  • End date
    Mar 28, 2023
  • participants needed
    300
  • sponsor
    Sorlandet Hospital HF
Updated on 28 October 2022

Summary

Induction of labor is an increasingly used intervention in obstetrics due to expanding indications, which more often includes relatively healthy women with uncomplicated pregnancies. While induction of labor traditionally is offered in an inpatient setting, a shift towards an outpatient setting is increasing despite insufficient evidence regarding safety and effectiveness. Oral misoprostol is easy for the pregnant women to administer and the risk of uterine hyperstimulation with fetal heart rate changes is found to be low. Strong evidence concludes that oral misoprostol is preferable as an induction agent and is recommended by the World Health Organization (WHO).

The investigators will perform a multicenter randomized-controlled trial comparing labor induction in an outpatient versus inpatient setting, aiming to increase knowledge on outpatient induction of labor with oral misoprostol. The study is based on experiences and findings from a recently performed pilot trial and targets a large group of relatively healthy pregnant women where induction of labor is decided.

The investigators hypothesize that women induced in an outpatient setting will be more satisfied than women induced in an inpatient setting.

Description

After induction of labor is decided the women will be recruited according to inclusion and exclusion criteria's.

The inpatient induction group will receive the following treatment:

Oral misoprostol 25ug every two hours and a cardiotocography for fetal monitoring every 4-6 hours until start of contractions, the next 48 hours while admitted to the maternity ward. The participating women will be transferred to the labor ward by start of contractions or need for closer fetal surveillance and/or analgesia.

The outpatient induction group will receive the following treatment:

These participating women receive the first oral misoprostol 25ug at the maternity unit. After two hours if the cardiotocograph is normal and there are no signs of contractions, these women go home. At home, the women will continue to take 25ug misoprostol every two hours until 22 pm or until the contractions begin. Maximum time spent at home is 48 hours and maximum number of tablets is 12 during this period (6 tablets each day). The women will also receive oral and written information regarding when to return to the maternity ward. Information sheets for the midwives and included women will be adapted from those used in the pilot study.

If the contractions are still absent after 48 hours or a maximum of 12 tablets (6 per day), all women (both inpatient and outpatient) are admitted to the maternity ward for further induction of labor. All women will receive equal standard of care including fetal surveillance after admittance to the hospital. Further follow up is in accordance with standard procedure of the maternity ward. Questions about fidelity to the proposed protocol across sites will be asked in the patient questionnaire.

Details
Condition Induction of Labor
Treatment Inpatient setting, Outpatient setting
Clinical Study IdentifierNCT05144048
SponsorSorlandet Hospital HF
Last Modified on28 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

≥ 37 gestational weeks, vertex presentation, single pregnancy
Age ≥ 18 years
Understand and read Norwegian
Distance to hospital less than 1 hour
Normal ultrasound including
fetal movements
amniotic fluid (deepest single vertical pocket) > 2 cm
estimated fetal weight ≥ -15% (≥ 10 percentile)
Normal antenatal cardiotocography
Women with stable hypertension and uncomplicated preeclampsia without indication for inpatient treatment can be included after individual assessment
Access to partner or contact person at home for transportation to hospital

Exclusion Criteria

Premature rupture of membranes
Uterine scar
BMI ≥ 40
Abnormal fetal Doppler (if examined); umbilical artery pulsatility index ≥ 95 percentile and/or cerebroplacental ratio <1
Fetal anomaly or chromosomic / genetic disorder
Grand multipara (P≥4)
Cognitive barriers
Pregnancy complications such as preeclampsia requiring in-hospital treatment, insulin dependent diabetes or other conditions associated with risk of fetal hypoxia during labor
Signs of infection or serious health problems
Favorable cervix and / or previous obstetric history providing contraindications for induction with misoprostol
Combined risk factors, individually evaluated by the attending obstetrician
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note